Minerva Neurosciences, Inc.
NERV
Rank in Stocks
#18681
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the... Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Share Price
$2.63
Last synced: 2026-11-09
Market Cap
$125.58M
Change (1 day)
8.68%
Change (1 year)
-33.75%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Minerva Neurosciences, Inc. (NERV)
Category
Healthcare
EPS for Minerva Neurosciences, Inc. (NERV)
EPS as of September 2026 TTM: $-26.07
According to Minerva Neurosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-26.07. At the end of 2025 the company had an EPS of $-34.67, a decrease compared to its 2024 EPS of $0.19.
EPS history for Minerva Neurosciences, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-26.07 | -24.81% |
| 2025 | $-34.67 | -18,347.37% |
| 2024 | $0.19 | -104.12% |
| 2023 | $-4.61 | -23.29% |
| 2022 | $-6.01 | -35.72% |
| 2021 | $-9.35 | -2,560.53% |
| 2020 | $0.38 | -102.57% |
| 2019 | $-14.80 | 43.00% |
| 2018 | $-10.35 | 55.64% |
| 2017 | $-6.65 | -15.61% |
| 2016 | $-7.88 | -14.81% |
| 2015 | $-9.25 | -63.16% |
| 2014 | $-25.11 | 1,655.94% |
| 2013 | $-1.43 | 107.25% |
| 2012 | $-0.69 | 40.82% |
| 2011 | $-0.49 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -160.07% |
US
|
|
| $-7.07 | -72.88% |
US
|
|
| $-5.29 | -79.71% |
AU
|
|
| $12.88 | -149.41% |
BE
|
|
| $21.56 | -182.70% |
NL
|
Questions about Minerva Neurosciences, Inc.'s earnings per share (EPS)
What is Minerva Neurosciences, Inc.'s earnings per share (EPS)?
Minerva Neurosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-26.07, as of Sep 2026.
What was Minerva Neurosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Minerva Neurosciences, Inc.'s earnings per share (EPS) was $-34.67, compared with $0.19 in 2024.
How has Minerva Neurosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Minerva Neurosciences, Inc.'s earnings per share (EPS) was highest in 2020 ($0.38) and lowest in 2025 ($-34.67).
How does Minerva Neurosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Minerva Neurosciences, Inc.'s earnings per share (EPS) ($-26.07) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.